Danaher Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Julie Sawyer Montgomery
- Full Time Employees
- 59,000
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 2200 Pennsylvania Avenue, NW Washington DC United States of America 20037-1701
- IPO Date
- Dec 29, 1978
- CIK
- 0000313616
- Website
- danaher.com
- Similar Companies
- Business
- Danaher Corporation (NYSE: DHR), founded in 1984 and headquartered in Washington, D.C., operates as a leading global science and technology innovator focused on life sciences and diagnostics. The company conducts business through three primary segments: biotechnology, which develops products and services for therapeutic development including bioprocessing solutions, plasmid DNA, mRNA, proteins, and genomic medicines via brands such as Cytiva, Aldevron, and Abcam; life sciences, offering instruments like mass spectrometers, flow cytometry systems, microscopes, genomics consumables, lab automation, centrifugation, particle characterization, and gene and cell therapy tools; and diagnostics, providing clinical instruments, reagents, consumables, software, and services for disease diagnosis in hospitals, physicians' offices, reference laboratories, and critical care settings through subsidiaries including Cepheid and Beckman Coulter. Danaher serves customers worldwide across biopharmaceutical, research, healthcare, and precision medicine markets, employing approximately 63,000 associates in over 125 countries. Recent developments include the 2023 acquisition of Abcam for proteomic research consumables to accelerate drug discovery; a January 2025 investment partnership with Innovaccer Inc. through Danaher Diagnostics LLC and Danaher Ventures LLC to advance AI-enabled diagnostics and precision medicine; and a May 2025 diagnostic development and commercialization alliance with AstraZeneca to scale next-generation AI-powered diagnostics solutions.
Company News
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
7,724 Shares of Danaher Corporation $DHR Purchased by Finward Bancorp
13,784 Shares of Danaher Corporation $DHR Purchased by B. Riley Wealth Advisors Inc.
3,232 Shares in Danaher Corporation $DHR Bought by Foster Group Inc.
Danaher Corporation $DHR Shares Newly Bought by Copeland Capital Management LLC
Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?
Danaher (DHR) Earnings Expected to Grow: Should You Buy?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
2 Beaten-Down Healthcare Stocks That Could Soar in the Fourth Quarter
How to Invest in AI Drug Discovery
19,344 Danaher Corporation $DHR Shares Acquired by NorthCrest Asset Manangement LLC
Danaher Corporation $DHR Shares Sold by Forvis Mazars Wealth Advisors LLC
Danaher Collaborates with NVIDIA to Advance Autonomous Science
2,832 Shares of Danaher Corporation $DHR Purchased by Value Investment Professionals LLC
Danaher Announces Appointments of Daniel Comas and Robert Hershberg to Board of Directors
Danaher Corporation $DHR Stake Boosted by Everhart Financial Group Inc.
Titleist Asset Management LLC Makes New Investment in Danaher Corporation $DHR
Danaher Corporation $DHR Stock Position Increased by CoreCap Advisors LLC
Vann Equity Management LLC Purchases New Position in Danaher Corporation $DHR
Chickasaw Capital Management LLC Buys 2,600 Shares of Danaher Corporation $DHR